Human T-cells recognise N-terminally Fmoc-modified peptide

Vaccine

Volumn 21, Issue 25-26, 2003, Pages 3638-3646

  Mannering, Stuart I ^a   Purcell, Anthony W ^b   Honeyman, Margo C ^a   McCluskey, James ^b   Harrison, Leonard C ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Fmoc; Peptides; T lymphocytes

Indexed keywords

ARGINYLGLYCYLISOLEUCYLVALYLGLUTAMYLGLUTAMINYLCYSTEINYLCYSTEINYLTHREONYLS ERI NE; GLYCYLISOLEUCYLVALYLGLUTAMYLGLUTAMINYLCYSTEINYLCYSTEINYLTHREONYLSERYLISO LEU CINE; ISOLEUCYLVALYLGLUTAMYLGLUTAMINYLCYSTEINYLCYSTEINYLTHREONYLSERYLISOLEUCIN E; LYSYLARGINYLGLYCYLISOLEUCYLVALYLGLUTAMYLGLUTAMINYLCYSTEINYLCYSTEINYLTHRE ONI NE; SERYLLEUCYLGLUTAMINYLLYSYLARGINYLGLYCYLISOLEUCYLVALYLGLUTAMYLGLUTAMINYLC YST EINYLCYSTEINYLTHREONYLSERYLISOLEUCINE; TRYPTOPHYLARGINYLGLYCYLISOLEUCYLVALYLGLUTAMYLGLUTAMINYLCYSTEINYLCYSTEINY LTH REONYLSERINE; 9 FLUORENYLMETHYL CHLOROFORMATE; 9 FLUORENYLMETHYLCHLOROFORMATE ARGINYLGLYCYLISOLEUCYLVALYLGLUTAMYLGLUTAMINYLCYSTEINYLCYSTEINYLTHREONYLSERINE; ARGINYLGLYCYLISOLEUCYLVALYLGLUTAMYLGLUTAMINYLCYSTEINYLCYSTEINYLTHREONINE; CD4 ANTIGEN; EPITOPE; GLYCYLISOLEUCYLVALYLGLUTAMYLGLUTAMINYLCYSTEINYLCYSTEINYLTHREONINE; GLYCYLISOLEUCYLVALYLGLUTAMYLGLUTAMINYLCYSTEINYLCYSTEINYLTHREONYLSERINE; ISOLEUCYLVALYLGLUTAMYLGLUTAMINYLCYSTEINYLCYSTEINYLTHREONYLSERINE; PROINSULIN; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VACCINE; VALYLGLUTAMYLGLUTAMINYLCYSTEINYLCYSTEINYLTHREONYLSERYLISOLEUCINE;

AMINO TERMINAL SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; CELL ISOLATION; CELL STIMULATION; CONTROLLED STUDY; DRUG SYNTHESIS; EPITOPE MAPPING; HLA SYSTEM; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; MALE; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN MODIFICATION; T LYMPHOCYTE;

EID: 0242380659     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00402-X     Document Type: Article

References (24)

1. Townsend A.R., Rothbard J., Gotch F.M., Bahadur G., Wraith D., McMichael A.J. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell. 44(6):1986;959-968.
2. Goulder P.J., Addo M.M., Altfeld M.A.et al. Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays. J. Virol. 75(3):2001;1339-1347.
3. Honeyman M.C., Brusic V., Stone N., Harrison L.C. Neural network-based prediction of candidate T-cell epitopes. Nat. Biotechnol. 16(10):1998;966-969.
4. Anderson R.P., Degano P., Godkin A.J., Jewell D.P., Hill A.V. In vivo antigen challenge in celiac disease identifies a single transglutaminase- modified peptide as the dominant A-gliadin T-cell epitope. Nat. Med. 6(3):2000;337-342.
5. Parmiani G., Castelli C., Dalerba P.et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst. 94(11):2002;805-818.
6. Tsuji M., Zavala F. Peptide-based subunit vaccines against pre-erythrocytic stages of malaria parasites. Mol. Immunol. 38(6):2001;433-442.
7. Engler O.B., Dai W.J., Sette A.et al. Peptide vaccines against hepatitis B virus: from animal model to human studies. Mol. Immunol. 38(6):2001;457-465.
8. α-amino and C-terminal carboxyl functions in solid-phase peptide synthesis. Biopolymers. 55(2):2000;123-139.
9. Notkins A.L., Lernmark A. Autoimmune type 1 diabetes: resolved and unresolved issues. J. Clin. Invest. 108(9):2001;1247-1252.
10. Harrison L.C., Chu S.X., de Aizpurua H.J., Graham M., Honeyman M.C., Colman P.G. Islet-reactive T-cells are a marker of preclinical insulin-dependent diabetes. J. Clin. Invest. 89(4):1992;1161-1165.
11. Roep B.O. T-cell responses to autoantigens in IDDM. The search for the Holy Grail. Diabetes. 45(9):1996;1147-1156.
12. Durinovic-Bello I., Hummel M., Ziegler A.G. Cellular immune response to diverse isleT-cell antigens in IDDM. Diabetes. 45(6):1996;795-800.
13. Cowley D.J., Mackin R.B. Expression, purification and characterization of recombinant human proinsulin. FEBS Lett. 402(2-3):1997;124-130.
14. Purcell A.W., Chen W., Ede N.J.et al. Avoidance of self-reactivity results in skewed CTL responses to rare components of synthetic immunogens. J. Immunol. 160(3):1998;1085-1090.
15. Purcell A.W., Gorman J.J. The use of post-source decay in matrix-assisted laser desorption/ionisation mass spectrometry to delineate T-cell determinants. J. Immunol. Methods. 249(1-2):2001;17-31.
16. Gorman JJ, Ferguson S, Lopaticki J, Pitt J, Purcell AW, Morrow CJ. Elucidation of functionally significant structural modifications by post-source decay and matrix-assisted laser desorption/ionisation time of flight mass spectrometry. In: Kamp RM, Kyriakidis D, Choli-Papadopouluo T, editors. Proteome and protein analysis. Berlin: Springer Verlag; 2000. p. 117-38.
17. Boehm U., Klamp T., Groot M., Howard J.C. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15:1997;749-795.
18. Cresswell P., Arunachalam B., Bangia N.et al. Thiol oxidation and reduction in MHC-restricted antigen processing and presentation. Immunol. Res. 19(2-3):1999;191-200.
19. Arunachalam B., Phan U.T., Geuze H.J., Cresswell P. Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon- inducible lysosomal thiol reductase (GILT). Proc. Natl. Acad. Sci. U.S.A. 97(2):2000;745-750.
20. Harduf Z., Nir T., Juven B.J. High-performance liquid chromatography of biogenic amines, derivatized with 9-fluorenylmethyl chloroformate. J. Chromatogr. 437(2):1988;379-386.
21. Matsuo H., Batocchi A.P., Hawke S. Peptide-selected T-cell lines from myasthenia gravis patients and controls recognize epitopes that are not processed from whole acetylcholine receptor. J. Immunol. 155(7):1995;3683-3692.
22. Nagvekar N., Corlett L., Jacobson L.W.et al. Scanning a DRB3*0101 (DR52a)-restricted epitope cross-presented by DR3: overlapping natural and artificial determinants in the human acetylcholine receptor. J. Immunol. 162(7):1999;4079-4087.
23. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol. Today. 19(9):1998;395-404.
24. Hiemstra H.S., van Veelen P.A., Willemen S.J. Quantitative determination of TCR cross-reactivity using peptide libraries and protein databases. Eur. J. Immunol. 29(8):1999;2385-2391.